a nonsignificant trendP = .092
Neoadjuvant therapy also demonstrated a nonsignificant trend toward worse outcomes with a HR of 3.347 (95% CI, 0.822-13.623; P = .092).
Neoadjuvant therapy also demonstrated a nonsignificant trend toward worse outcomes with a HR of 3.347 (95% CI, 0.822-13.623; P = .092).
Masaoka stage showed a trend toward significance with hazard ratio (HR) of 1.971 (95% CI, 0.890-4.368; P = .094), yet it did not reach statistical significance.
Age emerged as a potential factor influencing OS, approaching significance in univariate analysis, indicating that older patients might have inferior long-term survival.